10, Rue Vauquelin
75231 Paris Cedex 05
22 articles with HiFiBiO
HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
HiFiBiO Therapeutics announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO’s HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications.
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
FibroGen, Inc. and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.
6/16/2021Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week.
HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
HiFiBiO Therapeutics today announced the completion of an oversubscribed $75M Series D financing round.
HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody
HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody HFB30132A possesses differentiated properties providing strong potential for COVID-19 treatment and prevention
HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
HiFiBiO Therapeutics , a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first cohort of the Phase I study ( NCT04590430 ) of HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment and prevent
HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody
HiFiBiO Therapeutics , a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, today announced a partnership agreement with South Korea-based ABL Bio to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The two companies will join forces to drive the development of t
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
Research Collaboration will Leverage HiFiBiO’s Proprietary Single-Cell Platform to Identify Novel Targets to Support Kite’s Development of Cell Therapies in AML -- SANTA MONICA, Calif. & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML). Through this collaboratio
HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients
Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling platform to identify, engineer, and develop a novel therapy against SARS-CoV-2 ready for clinical studies in less than six months CAMBRIDGE, Mass.--( BUSINESS WIRE )-- HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, announced today the s
HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19
HiFiBiO Therapeutics , a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, today announced a collaboration with the Coronavirus
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II
HiFiBiO Therapeutics is presenting its three lead pipeline programs at the American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place today. The company is a pioneer of novel antibody drug disc
HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients
HiFiBiO Therapeutics will take a pioneering approach to clinical development of its pipeline of antibody candidates by using patient stratification biomarkers identified by the company’s proprietary Drug Intelligent Science (DIS™) CAMBRIDGE, Mass. & SHANGHAI & PARIS--( BUSINESS WIRE )-- Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders
Latest funding led by IDG Capital with participation from Sequoia Capital China, Delian Capital, Hanne Capital, VI Ventures, Legend Star Capital, LYFE Capital, and Kite, a Gilead Company
HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer
New Nature Genetics publication describes novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems
HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer
Victa Biotherapeutics is a new open-innovation joint venture designed to further validate Dr. Sukhatme’s pioneering immuno-oncology research in precision medicine applications
Companies join forces to target different T cell subsets and combat cancer.
Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer
Agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
Global pharmaceutical leader selects innovative single-B-cell technology to generate breakthrough therapies